SciELO - Scientific Electronic Library Online

vol.44 issue3Patients in Nursing Homes: type 2 diabetes mellitus prevalence and its pharmacologic therapyBiosimilars of monoclonal antibodies in inflammatory diseases and cancer: current situation, challenges, and opportunities author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google


Farmacia Hospitalaria

On-line version ISSN 2171-8695Print version ISSN 1130-6343


DIAZ-ACEDO, Rocío; ARTACHO-CRIADO, Silvia; GALVAN-BANQUERI, Mercedes  and  LOPEZ-ALVAREZ, Pilar. Real world study of pertuzumab-trastuzumab-chemotherapy versus trastuzumab-chemotherapy in neoadjuvant treatment of breast cancer. Farm Hosp. [online]. 2020, vol.44, n.3, pp.96-99.  Epub Oct 19, 2020. ISSN 2171-8695.


The primary objective of the study is to compare the effectiveness of trastuzumab-chemotherapy with and without pertuzumab. As a secondary objective, we seek to evaluate the cardiac safety of the treatment.


Retrospective observational study including all patients treated with either pertuzumab-trastuzumab-chemotherapy (n = 10) or trastuzumab-chemotherapy (n = 13) (January 2015-December 2018) in a specialty hospital, which met the criteria established by the Commission Central for the Optimization and Harmonization of the pharmacotherapy of the Andalusian Health Service for the use of pertuzumab in neoadjuvance: HER2 positive tumor, negative hormonal receptors, with high risk of relapse (tumor > 2 cm or lymph node involvement). To assess effectiveness, the complete pathological response was used. For cardiac safety, the decrease in left ventricular ejection fraction greater than 10% was employed.


Complete pathological response was superior in the pertuzumab group (70.0% vs. 30.8%). Cardiac safety was similar in both.


For patients with HER2 positive tumors and negative hormonal receptors with high risk criteria that receive pertuzumab, the complete pathological response is superior, with no increase in cardiac toxicity.

Keywords : Pertuzumab; Trastuzumab; Pathological complete response; Breast cancer; Neoadjuvance.

        · abstract in Spanish     · text in English | Spanish     · English ( pdf ) | Spanish ( pdf )